Company profile: Supernus Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical products for central nervous system diseases, developing and commercializing therapies including Qelbree for ADHD; Trokendi XR for epilepsy and migraine prevention; and Oxtellar XR for epilepsy, with pipeline candidates SPN-830 for hypomobility in Parkinson’s disease, SPN-820/821 for treatment-resistant depression, and SPN-817 for severe epilepsy.
Products and services
- Oxtellar XR: Extended-release medication used for the treatment of epilepsy, delivering sustained-release dosing to support seizure management in patients with epilepsy
- Qelbree: Pharmaceutical-grade medication used for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in children and adults, enabling therapeutic care across pediatric and adult ADHD populations
- Trokendi XR: Extended-release medication used for the treatment of epilepsy and migraine prevention, delivering sustained release to manage seizures and help prevent migraine episodes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Supernus Pharmaceuticals
Quoin Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical products under development addressing major unmet medical needs, including QRX003, a topical lotion in clinical evaluation for Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma; QRX008 for Scleroderma; QRX007 for Netherton Syndrome; and QRX004 for Epidermolysis Bullosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quoin Pharmaceuticals company profile →
Protagenic Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions developing naturally occurring human brain hormones to treat anxiety- and depression-based mood disorders. Offers PT00114, a synthetic analog of the neuropeptide TCAP that regulates stress response for depression, PTSD, anxiety, and addiction, and the TCAP R&D platform to address neuropsychiatric and neurodegenerative diseases at the cellular level in the brain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protagenic Therapeutics company profile →
Mynd Life Sciences
HQ: Canada
Website
- Description: Provider of biomarker diagnostic tests for postpartum depression and early Alzheimer’s detection, psilocybin-based drug R&D targeting central nervous system diseases, and intellectual property on inflammation-regulating gene pathways to support treatments for neuroinflammatory diseases; also developing at-home tests to monitor inflammation and aid health management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mynd Life Sciences company profile →
Allon Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage biopharmaceutical drug development for neurodegenerative diseases, with lead product Davunetide intranasal in Phase IIa clinical trials for Alzheimer's disease, schizophrenia cognitive impairment, and frontotemporal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allon Therapeutics company profile →
Freespira
HQ: United States
Website
- Description: Provider of the only FDA-cleared, at-home, drug-free digital therapeutic proven to significantly reduce or eliminate panic attacks, panic disorder, and PTSD symptoms in 28 days. The Freespira treatment uses a sensor and tablet to normalize breathing. Also offers resources for health plans, employees, and individuals, a veterans relief program, and a provider referral program with insurance coverage information.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freespira company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Supernus Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Supernus Pharmaceuticals
2.2 - Growth funds investing in similar companies to Supernus Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Supernus Pharmaceuticals
4.2 - Public trading comparable groups for Supernus Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →